

Food and Drug Administration
Center for Drug Evaluation and Research
Oncologic Drugs Advisory Committee Meeting
FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center
(Rm. 1503), Silver Spring, MD
May 2, 2013

DRAFT MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Caleb Briggs, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs
Center for Drug Evaluation and Research

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Deborah K. Armstrong, MD

Associate Professor of Oncology
The Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins
The Johns Hopkins University School of
Medicine
Baltimore, Maryland

Frank Balis, MD

The Louis and Amelia Canuso Family Endowed
Chair for Clinical Research in Oncology
The Children's Hospital of Philadelphia
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Aman U. Buzdar, MD

Vice President Clinical Research and Interim
Professor of Medicine
MD Anderson Cancer Center
Dept. of Breast Medical Oncology
Houston, Texas

Louis F. Diehl, MD

Professor of Medicine
Duke University Medical Center
Durham, North Carolina

Tito Fojo, MD, PhD

Program Director, Medical Oncology
National Cancer Institute
Bethesda, Maryland

James Liebmann, MD

Assistant Professor of Medicine
Department of Medicine
University of Massachusetts
Worcester, Massachusetts

Brent Logan, PhD

Professor of Biostatistics
Division of Biostatistics
Medical College of Wisconsin
Milwaukee, Wisconsin

Michael Menefee, MD

Assistant Professor
Division of Hematology and Oncology
Mayo Clinic
Jacksonville, Florida

Mikkael Sekeres, MD, MS

(Chairperson)
Associate Professor of Medicine
Staff, Cleveland Clinic Taussig Cancer Institute
Department of Hematologic Oncology and
Blood Disorders
Cleveland, Ohio

David Steensma, MD

Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Food and Drug Administration
Center for Drug Evaluation and Research
Oncologic Drugs Advisory Committee Meeting
May 2, 2013

DRAFT MEETING ROSTER (cont.)

Antoinette J. Wozniak, MD, FACP

(Afternoon Session Only)

Professor, Department of Oncology,
Wayne State University School of Medicine, and
Karmanos Cancer Institute
Detroit, Michigan

Jane Zones, PhD

(Consumer Representative)

Medical Sociologist (retired)
Breast Cancer Action
National Women's Health Network
San Francisco, California

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER

(Non-Voting)

Howard Fingert, MD, FACP

(Industry Representative)

Senior Medical Director, Clinical Intelligence
Millennium, the Takeda Oncology Company
Cambridge, Massachusetts

TEMPORARY MEMBERS (Voting)

Cynthia Chauhan (Afternoon Session Only)

(Patient Representative)

Wichita, Kansas

Wen-Jen Hwu, MD, PhD (Afternoon Session

Only)

Professor
MD Anderson Cancer Center
Department of Melanoma Medical Oncology
Houston, Texas

Lori Dodd, PhD (Morning Session Only)

Mathematical Statistician
Division of Clinical Research, Biostatistics
Research Branch
National Institute of Allergy and Infectious
Diseases
National Institutes of Health
Bethesda, Maryland

Dan Lumley, EdD (Morning Session Only)

(Patient Representative)

Kansas City, Missouri

Marc Garnick, MD (Morning Session Only)

Beth Israel Deaconess Medical Center
Clinical Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Kenneth Najarian, MD

(Participating via Telephone)

(Afternoon Session Only)

Professor of Radiology
University of Vermont College of Medicine
Burlington, Vermont

Food and Drug Administration
Center for Drug Evaluation and Research
Oncologic Drugs Advisory Committee Meeting
May 2, 2013

DRAFT MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting) (cont.)

Takami Sato, MD, PhD (Afternoon Session Only)

K. Hasumi Professor of Medical Oncology
Department of Medical Oncology
Jefferson Medical College of Thomas Jefferson
University
Philadelphia, Pennsylvania

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director
Office of Hematology & Oncology Products
(OHOP),
Office of New Drugs (OND), CDER, FDA

Amna Ibrahim, MD (Morning Session Only)

Deputy Director
Division of Oncology Products 1 (DOP1),
OHOP, OND, CDER, FDA

V. Ellen Maher, MD (Morning Session Only)

Medical Team Leader
DOP1, OHOP, OND, CDER, FDA

Jonathan Jarow, MD (Morning Session Only)

Medical Officer
DOP1, OHOP, OND, CDER, FDA

J. Dawn Arrington, MD (Morning Session Only)

Medical Officer
DOP1, OHOP, OND, CDER, FDA

Patricia Keegan, MD (Afternoon Session Only)

Director
Division of Oncology Products 2 (DOP2),
OHOP, OND, CDER, FDA

Joseph Gootenberg, MD (Afternoon Session Only)

Deputy Director
DOP2, OHOP, OND, CDER, FDA

Martin Cohen, MD (Afternoon Session Only)

Medical Officer
DOP2, OHOP, OND, CDER, FDA

Geoffrey Kim, MD (Afternoon Session Only)

Medical Officer
DOP1, OHOP, OND, CDER, FDA